Profound Medical Corp. reported that its CAPTAIN randomized controlled trial met its primary safety endpoint, showing that 50 % of men treated with the TULSA Procedure preserved erectile potency and urinary continence at six months, compared with 24 % of men who underwent robotic radical prostatectomy. The trial enrolled 211 patients across 23 sites—20 in the United States, two in Canada and one in Europe—providing a robust, guideline‑grade evidence base for the TULSA technology.
Continue reading for full analysis...
Profound Medical Corp. (NASDAQ:PROF) reported its fourth‑quarter 2025 results, posting earnings per share of $-0.27, exactly in line with the consensus estimate of $-0.27. Revenue totaled $6.0 million, falling short of analyst expectations that ranged from $6.9 million to $10.5 million.
Continue reading for full analysis...